Alberto Rivera, MD, FAAPMR

Al Rivera, MD, FAAPMR, came to medicine with a single animating conviction: that the human body carries within it the answers to its own suffering, and that the clinician's task is to read those answers at the level where they are written, in the genome, the cell, and the signaling cascade running beneath every symptom a patient can name. That conviction did not begin in a clinic. It began in a laboratory.

Before earning his medical degree, Dr. Rivera was already working at the bench. At Columbia University, under the supervision of Dr. Calame, he participated in research examining the role of C/EBP proteins, transcription factors that sit at the intersection of cellular differentiation, immune regulation, and inflammatory gene expression. That early immersion in transcriptional biology planted in him a lasting orientation toward the molecular events that precede and organize disease. He then joined a research initiative focused on the use of restriction enzymes to cleave the HIV virus, work that placed him at the edge of one of the most urgent biological problems of the 1990s and gave him a deep familiarity with the logic of nucleic acid targeting and viral biology. He subsequently collaborated with Dr. Fernandez on a project identifying apoptosis of Sertoli cells occurring ten years after vasectomy, work that required precision in cellular pathology and an eye for the long biological consequences of structural intervention. He then joined Dr. Appleyard in evaluating the permeability of the colonic mucosa in rats with ulcerative colitis, an investigation into barrier biology and inflammatory tissue dynamics that would later find deep resonance in his clinical thinking about systemic inflammation.

He earned his medical degree from the Ponce School of Medicine, where his formation as a clinician built directly on the scientific discipline those research years had established. He completed his internship at San Luke's Hospital, and then entered his residency in Physical Medicine and Rehabilitation at Nassau University Medical Center, where he rose to the position of Chief Resident. His residency years were marked by intellectual productivity, including multiple poster presentations that announced early the range and rigor of his clinical thinking. Following residency, he pursued further subspecialty training at the University of Florida, where he deepened his expertise in Interventional Pain Medicine. Among the figures who shaped his approach during this period were Dr. William Seeds and Dr. Thierry Hertoghe, whose work in precision medicine gave him the tools to think beyond symptom management toward root-cause biological intervention.

As early as 2006, well before precision medicine entered the mainstream clinical conversation, Dr. Rivera was designing targeted nutritional interventions for patients living with chronic pain. His early formulations were directed specifically toward people suffering from failed back syndrome, chronic low back pain, and fibromyalgia, populations that the conventional pharmacological armamentarium had consistently underserved. That work was the first expression of a clinical philosophy that would take twenty more years to reach its full articulation: that chronic pain is a metabolic and genomic phenomenon, and that the cell must be fed before it can heal.

He built his clinical home at Promethium Medical, the practice he founded in Florida, where he developed a patient population defined by complexity. These were patients carrying chronic inflammatory disease, persistent pain, and the layered pathology of conditions such as Long COVID, who arrived after conventional frameworks had offered them incomplete resolution. The common thread running through their presentations was a systemic upstream failure he identified as the Oxygen Free Radical Crisis, a polygenic state in which antioxidant, methylation, detoxification, and inflammatory regulatory pathways converge in a cascade of oxidative injury that drives disease across every tissue the body possesses. Dr. Rivera has lectured on this framework nationally and internationally, arguing that the Oxygen Free Radical Crisis represents nothing less than the universal human disease, the shared biological substrate from which the full spectrum of chronic illness emerges.

That clinical insight became the foundation of GENEFLAMMATION, a precision genomics platform Dr. Rivera built to translate polygenic risk into individualized therapeutic strategy. GENEFLAMMATION operates across SNP-based genotyping of the key pathways governing oxidative stress and inflammatory regulation, and its flagship offering, The Inflammation Protocol, delivers a personalized genomic profile with therapeutic implications tailored to each patient's specific genetic architecture. The laboratory infrastructure supporting this work includes a Tecan Freedom EVO liquid handling system, a QuantStudio 12K Flex real-time PCR instrument, and a KingFisher Flex magnetic particle processor, all configured for high-throughput SNP-based genotyping workflows.

Dr. Rivera is also the author of Primal Fuel, a nutritional formulation he developed from the same oxidative stress biology that anchors GENEFLAMMATION, designed to address the cellular fuel deficits that accompany chronic inflammatory states and carrying forward the nutritional science he began developing in 2006.

He currently serves as principal investigator of the Cognify Trial, in which he administers the monoclonal antibody TB-006 to patients living with Alzheimer's disease. The trial reflects his conviction that neuroinflammation and the oxidative cascades driving neurodegeneration belong to the same upstream biology he has spent his career characterizing, and that precision immunological intervention at that level offers a path forward that symptomatic approaches cannot provide.

Dr. Rivera lectures nationally and internationally on genomics, oxidative stress biology, chronic pain, regenerative medicine, and the clinical application of precision inflammation medicine. His lectures draw audiences of physicians, researchers, and allied health professionals who recognize in his work a coherent biological framework for conditions that have long resisted coherent explanation. He brings to every platform the same quality of attention he brings to a complex patient presentation: precise, curious, and always oriented toward the next question the evidence demands he ask.